Prediction of adverse events risk in patients with comorbid post-traumatic stress disorder and alcohol use disorder using electronic medical records by deep learning models.

Journal: Drug and alcohol dependence
PMID:

Abstract

BACKGROUND: Identifying co-occurring mental disorders and elevated risk is vital for optimization of healthcare processes. In this study, we will use DeepBiomarker2, an updated version of our deep learning model to predict the adverse events among patients with comorbid post-traumatic stress disorder (PTSD) and alcohol use disorder (AUD), a high-risk population.

Authors

  • Oshin Miranda
    Computational Chemical Genomics Screening Center, Department of Pharmaceutical Sciences/School of Pharmacy, University of Pittsburgh, Pittsburgh, PA 15213, USA.
  • Peihao Fan
    Department of Pharmaceutical Sciences and Computational Chemical Genomics Screening Center, School of Pharmacy, University of Pittsburgh, Pittsburgh, Pennsylvania, United States of America.
  • Xiguang Qi
    Computational Chemical Genomics Screening Center, Department of Pharmaceutical Sciences/School of Pharmacy, University of Pittsburgh, Pittsburgh, PA 15213, USA.
  • Haohan Wang
    Language Technologies Institute, Carnegie Mellon University, Pittsburgh, PA, USA†Equal Contribution, haohanw@cs.cmu.edu.
  • M Daniel Brannock
    RTI International, Durham, NC 27709, USA.
  • Thomas Kosten
    Menninger Department of Psychiatry, Baylor College of Medicine, Houston, TX 77030, USA.
  • Neal David Ryan
    Department of Psychiatry, School of Medicine, University of Pittsburgh, Pittsburgh, PA 15213, USA.
  • Levent Kirisci
    Department of Pharmaceutical Sciences, School of Pharmacy, University of Pittsburgh, 3501 Terrace St, Pittsburgh, PA, 15213, USA.
  • Lirong Wang
    Department of Pharmaceutical Sciences and Computational Chemical Genomics Screening Center, School of Pharmacy, University of Pittsburgh, Pittsburgh, PA 15261, USA; NIDA National Center of Excellence for Computational Drug Abuse Research, University of Pittsburgh, Pittsburgh, PA 15261, USA; Drug Discovery Institute, University of Pittsburgh, Pittsburgh, PA 15261, USA. Electronic address: liw30@pitt.edu.